Corrigendum re "Impact of Body Mass Index on Survival Outcomes for Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis" [Eur Urol Open Sci 2022;39:62-71]
- PMID: 36583180
- PMCID: PMC9793202
- DOI: 10.1016/j.euros.2022.12.001
Corrigendum re "Impact of Body Mass Index on Survival Outcomes for Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis" [Eur Urol Open Sci 2022;39:62-71]
Abstract
[This corrects the article DOI: 10.1016/j.euros.2022.03.002.].
© 2022 The Author(s).
Erratum for
-
Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis.Eur Urol Open Sci. 2022 Apr 4;39:62-71. doi: 10.1016/j.euros.2022.03.002. eCollection 2022 May. Eur Urol Open Sci. 2022. PMID: 35528786 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
